Kersten, M. J., Vermaat, J., Mutsaers, P., Kuipers, M., Willems, E., Anguille, S., Dekker, T., Jacobson, C., Bishop, M., Vandenberghe, P., Dachy, G., Klein, A., Arnason, J., Milatos, S., Lobetti-Bodoni, C., Santermans, E., Blum, S., Hoorde, K. V., Spoon, M., Fasan, O., Dreyling, M. (2025). High complete response rates and minimal residual disease (MRD) negativity, with durable responses, in high-risk mantle cell lymphoma (MCL) with GLPG5101, a fresh, early memory-enriched CAR T-cell therapy with a 7-day vein-to-vein time: Results from the ATALANTA-1 MCL cohort. Blood. https://doi.org/10.1182/blood-2025-662